You have successfully logged out.

Hello !
Logout

Peripheral Angioplasty

Combination therapy for endovascular procedures

Leave almost nothing behind by using Aperta NSE™ PTA scoring balloon catheter for lesion preparation in combination with SeQuent® Please OTW for drug delivery in patients with peripheral artery disease.

Product picture of SeQuent® Please OTW

Learn more about related products

SeQuent® Please OTW

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease (PAD) in above and below the knee indications. [1, 2]As pioneers and global market leaders in drug-coated balloon catheter technologies that help interventionalists achieve the treatment strategy of leaving (almost) nothing behind, B. Braun brings extensive knowledge to the peripheral field with the SeQuent® Please OTW.An effective next generation combination of Paclitaxel and Resveratrol [1,2]SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease.Long-term efficacy with short-term drug release [1,2]Paclitaxel with an effective drug dose of 3μg/mm² [3,4]Significant reduction of TLR and in late lumen loss (LLL) compared to uncoated balloons [1,2,5]Resveratrol: A naturally occurring matrix builderNaturally occurring, plant-based substance found for example in the skin of red grapes & raspberries [5]Acts as matrix builder and makes the Paclitaxel bioavailable [5]Enables fast and effective drug transfer into vessel wall [5]Mechanically resistant coating (5)Homogeneous coating even in the balloon folds exceeding distal and proximal markers [5]Low drug loss in simulated use [5]Efficient available drug dose at inflation [1,2,5]CONSEQUENT Demonstrates Safety and EfficacySafety and efficacy of SeQuent® Please OTW was demonstrated in an unselected, all comers cohort [2] whereas two-year efficacy and safety was shown in the CONSEQUENT RCT [1,4].

Interested?

Get in touch with one of our team

Contact Us

References

  1. Data on file at GOODMAN Co. Ltd.
  2. Ashida K et al. J Invasive Cardiol. 2013 Oct;25(10):555-64. PMID: 24088433.
  3. Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-14. 
  4. Langhoff R et al. Angiology. 2021 Mar 29:3319721997314. 
  5. Tepe G et al. N Engl J Med. 2008 Feb 14;358(7):689-99. 
  6. Tepe G et al. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1535-44. 
  7. Data on file at B. Braun.